Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Renu Eapen discussing the optimal management of de-novo ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Early results support a fully-powered trial of 18F-PSMA PET/CT for prostate cancer detection, according to the investigators. PSMA-PET/CT with the radiotracer 18F-DCFPyl (18 F-PSMA PET/CT) may improve ...
Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...
The IAEA is launching a year-long coordinated research project to develop computed tomography-based guidelines on prostate cancer contouring — a critical step in the cancer treatment process that ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
When planning for palliative radiotherapy, clinicians can forgo an additional CT scan on the same day as treatment and instead use a recent diagnostic CT scan, according to a results from a randomized ...
Prostate cancer is one of the most common cancers worldwide and remains a significant cause of cancer-related death. With increasing life expectancy, its incidence is projected to rise steadily in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results